EWTX
Price:
$28.7
Market Cap:
$2.69B
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.[Read more]
Industry
Biotechnology
IPO Date
2021-03-26
Stock Exchange
NASDAQ
Ticker
EWTX
According to Edgewise Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -28.01%. This represents a change of 275.87% compared to the average of -7.45% of the last 4 quarters.
The mean historical ROE of Edgewise Therapeutics, Inc. over the last ten years is 11.22%. The current -28.01% ROE has changed -349.66% with respect to the historical average. Over the past ten years (40 quarters), EWTX's ROE was at its highest in in the December 2020 quarter at 18.98%. The ROE was at its lowest in in the March 2020 quarter at -13.61%.
Average
11.22%
Median
-4.44%
Minimum
-31.42%
Maximum
56.29%
Discovering the peaks and valleys of Edgewise Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 607.43%
Maximum Annual ROE = 56.29%
Minimum Annual Increase = -130.10%
Minimum Annual ROE = -31.42%
Year | ROE | Change |
---|---|---|
2023 | -31.42% | 607.43% |
2022 | -4.44% | -71.08% |
2021 | -15.36% | -130.10% |
2020 | 51.03% | -9.34% |
The current ROE of Edgewise Therapeutics, Inc. (EWTX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-17.07%
5-year avg
11.22%
10-year avg
11.22%
Edgewise Therapeutics, Inc.’s ROE is greater than Century Therapeutics, Inc. (-65.37%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Talaris Therapeutics, Inc. (-36.43%), greater than Adicet Bio, Inc. (-63.95%), greater than Vor Biopharma Inc. (-86.42%), greater than Ikena Oncology, Inc. (-42.81%), greater than Design Therapeutics, Inc. (-18.48%), greater than Xilio Therapeutics, Inc. (-176.51%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Decibel Therapeutics, Inc. (-84.03%), greater than Celcuity Inc. (-60.83%), greater than TCR2 Therapeutics Inc. (-89.51%), greater than Revolution Medicines, Inc. (-34.57%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than Atreca, Inc. (-195.22%), greater than Passage Bio, Inc. (-70.73%),
Company | ROE | Market cap |
---|---|---|
-65.37% | $125.38M | |
-44.60% | $357.78M | |
-42.61% | $682.75M | |
-28.37% | $945.60M | |
-36.43% | $116.44M | |
-63.95% | $116.60M | |
-86.42% | $47.09M | |
-42.81% | $81.56M | |
-18.48% | $265.55M | |
-176.51% | $35.17M | |
-47.03% | $342.68M | |
-48.25% | $85.22M | |
-84.03% | $123.37M | |
-60.83% | $561.75M | |
-89.51% | $58.11M | |
-34.57% | $8.16B | |
-69.08% | $203.98M | |
-195.22% | $3.57M | |
-70.73% | $37.25M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Edgewise Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Edgewise Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Edgewise Therapeutics, Inc.'s ROE?
How is the ROE calculated for Edgewise Therapeutics, Inc. (EWTX)?
What is the highest ROE for Edgewise Therapeutics, Inc. (EWTX)?
What is the 3-year average ROE for Edgewise Therapeutics, Inc. (EWTX)?
What is the 5-year average ROE for Edgewise Therapeutics, Inc. (EWTX)?
How does the current ROE for Edgewise Therapeutics, Inc. (EWTX) compare to its historical average?